Trial Profile
A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; PTX 200 (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Prescient Therapeutics
- 03 Apr 2024 Status changed from recruiting to completed.
- 08 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 08 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.